Cancer Therapy
Advanced cancer patients with dyspnea treated with midazolam as adjunct therapy to morphine
Published in Clinical Oncology Week, May 1st, 2006
According to recent research from the United States, "The mainstay of dyspnea palliation remains altering its central perception. Morphine is the main drug and anxiolytics have a less established role. This trial assessed the role of midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in terminally ill cancer patients."
"One hundred and one patients with severe dyspnea were randomized to receive around-the-clock morphine (2.5 mg every 4 hours for opioid-naive) patients or a 25%...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Breast Cancer
Breast cancer risk reduced by selective cyclooxygenase-2 (COX-2) inhibitors - Esophageal Cancer
Esophageal cancer treated by higher frequency miniprobe and endoscopic submucosal dissection - Germ Cell Tumors
Germ cell tumors treated by continuous infusion of cisplatin linked to low ototoxicity - Prostate Cancer
Prostate cancer risk might not be reduced by regular use of aspirin - Adrenal Adenoma & Myelolipoma
Patient with adrenal adenoma plus myelolipoma relieved of hypertension by adrenalectomy - Angiogenesis
Data from angiogenesis program using cell labeling technology reported at conference - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
